Abstract:ObjectiveTo evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia.DesignMulticentre, open label, randomised trial.Setting15 hospitals in China between December 2017 and December 2020.Participants412 patients with newly diagnosed type 2 diabetes and significant hyperglycaemia (HbA1c ≥8.5%).InterventionsAll randomised participants initially received SIIT for 2-3 weeks, followed by linagliptin 5 mg/day, metformin 1000 mg/day, combination linagliptin plus metformin, or lifestyle modification alone (control) for 48 weeks.Main outcome measuresThe primary outcome was the percentage of participants achieving HbA1c <7.0% at week 48 after SIIT. Secondary outcomes included glycaemic control, β cell function, and variations in insulin sensitivity.Results412 participants were randomised. At baseline, the mean age was 46.8 (standard deviation 11.2) years, mean body mass index was 25.8 (2.9), and mean HbA1c was 11.0% (1.9%). At week 48, 80% (78/97), 72% (63/88), and 73% (69/95) of patients in the linagliptin plus metformin, linagliptin, and metformin groups, respectively, achieved HbA1c <7.0%, compared with 60% (56/93) in the control group (P=0.02 overall; P=0.003 for linagliptin plus metformin versus control; P=0.12 for linagliptin versus control; P=0.09 for metformin versus control). Additionally, 70% (68/97), 68% (60/88), and 68% (65/95) of patients in the linagliptin plus metformin, linagliptin, and metformin group, respectively, achieved HbA1c <6.5% compared with 48% (45/93) in the control group (P=0.005 overall; P=0.005 for linagliptin plus metformin versus control; P=0.01 for linagliptin versus control; P=0.008 for metformin versus control; all were significant after adjustment for multiple comparisons). Thus, compared with the control group, participants in the linagliptin plus metformin group were more likely to achieve HbA1c <7.0% at week 48 (odds ratio 2.78, 95% confidence interval 1.37 to 5.65; P=0.005). Moreover, the linagliptin plus metformin group showed the most significant improvement in fasting plasma glucose and β cell function indices. All treatments were well tolerated.ConclusionsThe intense simplified strategy using subsequent oral therapies post-SIIT, especially the linagliptin plus metformin combination, sustainably improved glycaemic control and β cell function in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia. This approach offers a promising direction for decision making in the clinical management of type 2 diabetes mellitus.Trial registrationClinicalTrials.gov NCT03194945

Diabetes remission in newly diagnosed type 2 diabetes mellitus through short‐term continuous subcutaneous insulin infusion intensive therapy combined with low‐carbohydrate diet treatment

Clinical observation and nursing care on patients with type 2 diabetes applied as continuous subcutaneous insulin infusion

Changes of Blood Pressure,blood Glucose and Blood Lipids Levels after Intensive Treatment in Incipient Diabetes II Patients

Remission of Hyperglycemia Following Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetic Patients: a Long-Term Follow-Up Study.

[Influencing Factors for the Curative Effects of Short-Term Continuous Subcutaneous Insulin Infusion on Newly Diagnosed Type 2 Diabetes].

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients is Associated with Improvement of Beta-Cell Function.

Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials

Application of Continuous Subcutaneous Insulin Infusion in Newly Versus Previously Diagnosed Type 2 Diabetes

[The Effects of Early Intensive Therapy on Islet Beta Cell Function and Long-Term Glycemia Control in Newly Diagnosed Type 2 Diabetic Patients with Different Fasting Plasma Glucose Levels.].

Effect of treating hyperglycemia of type 2 diabetes with continuous subcutaneous insulin infusion

The Effects of Continuous Subcutaneous Insulin Infusion on Metabolism of Glucose and Lipid in Patients with Type 2 Diabetes

Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function

Induction of Long-Term Good Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment

Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial

The Comparison of the Β-Cell Function Between Continuous Subcutaneous Insulin Infusion and Multiple Daily Infusion on Newly Diagnosed Type 2 Diabetic Patients Given Short-term Intensive Therapy

The Clinical Outcome of Early Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes

A Randomized Trial of Insulin Glargine Plus Oral Hypoglycemic Agents Versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.

1032-P: Time-in-Range during Short-Term Intensive Insulin Therapy Is Associated with Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes

Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial

Efficacy Observation of the Intensivetherapy of Short-acting Insulin for 32 Patients with Type 2 Diabetes